Page 41 - Flipbook

OS and PFS benefit with avelumab 1L maintenance irrespective

of 1L chemotherapy regimen

Gemcitabine + cisplatin (n=389) Gemcitabine + carboplatin (n=269)
100 100
90 Median OS (95% CI), months 90 Median OS (95% CI), months
80 Avelumab + BSC 25.3 (18.6–NE) 80 Avelumab + BSC 19.9 (16.0–24.0)
70 BSC alone 16.5 (13.4–26.8) 70 BSC alone 12.9 (9.4–16.2)
60 HR 0.69 (95% CI, 0.51–0.94) 60 HR 0.66 (95% CI, 0.47–0.91)
OS, % 50 OS, % 50
40 40
30 30
20 20
10 10
0 0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
No. at risk Months No. at risk Months
Avelumab + BSC 183 180 169 157 141 122 103 89 77 66 49 38 32 22 14 8 5 3 2 0 Avelumab + BSC 147 142 130 119 102 88 78 68 59 48 32 21 16 14 9 6 5 1 1 0
BSC 206 199 182 165 142 116 92 76 63 48 42 34 23 17 11 8 6 2 1 0 BSC 122 114 104 91 72 57 52 42 36 29 20 15 13 12 6 3 3 0
100 100
90 Median PFS (95% CI), months 90 Median PFS (95% CI), months
80 Avelumab + BSC 4.6 (3.6–6.8) 80
70 BSC alone 2.0 (1.9–3.6) 70 Avelumab + BSC 3.0 (2.0–3.7)
BSC alone
1.9 (1.9–2.0)
60 HR 0.63 (95% CI, 0.50–0.81) 60 HR 0.59 (95% CI, 0.44–0.80)
PFS, % 50 PFS, % 50
40 40
30 30
20 20
10 10
0 0
0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38
No. at risk Months No. at risk Months
Avelumab + BSC 183 112 85 67 49 40 34 27 26 23 18 17 13 7 3 2 1 1 0 Avelumab + BSC 147 72 48 41 33 25 20 18 16 9 7 6 3 1 0
BSC 206 88 58 39 28 22 17 14 12 11 7 7 4 2 1 1 1 0 BSC 122 42 22 8 7 5 5 4 3 3 1 1 1 0
BSC, best supportive care; CI, confidence interval; HR, hazard ratio; NE, not estimable; OS, overall survival; PFS, progression-free survival. OS and PFS were measured post
randomisation (after chemotherapy).
Grivas P, et al. Oral presentation at ESMO Virtual Congress 2020.